Key Takeaways Cagrilintide is a long-acting amylin analogue with clinical trial doses ranging from 0.3 mg to 4.5 mg weekly, while retatrutide is a triple agonist studied at 4 mg, 8 mg, and 12 mg weekly doses No published clinical trials currently exist evaluating the cagrilintide dosage with retatrutide combination, making any combined use experimental and off-label Both peptides work through different mechanismscagrilintide activates amylin receptors while retatrutide targets GIP, GLP-1, and glucagon receptorssuggesting potential complementary effects Gastrointestinal side effects (nausea, vomiting) occur in 60-80% of participants at higher doses for both compounds, raising concerns about additive effects when combined Proper dose escalation protocols spanning 8-20 weeks are critical for tolerability and adherence in peptide-based metabolic therapies Understanding Cagrilintide: Mechanism and Dosage Fundamentals What Is Cagrilintide
The foundational patent work by Harding et al
However, if youre getting B12 shots for general wellness, like improving energy or metabolism, its typically considered an elective treatment and paid for out-of-pocket
MOTS-c is a mitochondrial peptide that improves insulin sensitivity, supports fat oxidation, and boosts endurance